Get the Stockscreener App
5.69
6.36%
0.34
After Hours:
5.72
0.03
+0.53%
Ardelyx Inc stock is traded at $5.69, with a volume of 3.86M.
It is up +6.36% in the last 24 hours and down -1.39% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$5.35
Open:
$5.43
24h Volume:
3.86M
Relative Volume:
1.03
Market Cap:
$1.26B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-47.42
EPS:
-0.12
Net Cash Flow:
$-63.80M
1W Performance:
+15.65%
1M Performance:
-1.39%
6M Performance:
-15.70%
1Y Performance:
+32.02%
1-Day Range:
$5.32
$5.725
1-Week Range:
$4.82
$5.725
52-Week Range:
$4.06
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.69 | 1.26B | 251.85M | -72.58M | -63.80M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx CEO Michael Raab sells $134,482 in stock - Investing.com
Rubric Capital Management LP Buys 1,243,606 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Propel Bio Management LLC Has $7.38 Million Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It (NASDAQ:ARDX) - Seeking Alpha
Principal Financial Group Inc. Sells 336,014 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Insider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 31,980 Shares of Stock - MarketBeat
Ardelyx's regulatory officer sells $23,689 in stock By Investing.com - Investing.com Australia
Ardelyx CEO Michael Raab sells $153,328 in common stock By Investing.com - Investing.com Nigeria
Ardelyx executive sells $33,782 in stock - Investing.com India
Ardelyx executive sells $33,782 in stock By Investing.com - Investing.com South Africa
Ardelyx's regulatory officer sells $23,689 in stock - Investing.com India
Ardelyx, Inc. (NASDAQ:ARDX) CFO Sells $25,195.40 in Stock - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Insider Laura A. Williams Sells 7,366 Shares - MarketBeat
Ardelyx chief development officer sells $34,443 in stock By Investing.com - Investing.com Nigeria
Ardelyx chief medical officer sells $35,316 in stock By Investing.com - Investing.com Nigeria
Ardelyx CFO Justin Renz sells $25,219 in stock By Investing.com - Investing.com South Africa
Ardelyx CFO Justin Renz sells $25,219 in stock - Investing.com India
Ardelyx chief medical officer sells $35,316 in stock - Investing.com
Ardelyx chief development officer sells $34,443 in stock - Investing.com
Ardelyx Independent Chairman of the Board Acquires 18% More Stock - Simply Wall St
Ardelyx, Inc Announces Executive Changes - Marketscreener.com
Shareholders of Ardelyx, Inc. Should Contact The Gross Law Firm - GuruFocus.com
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - GuruFocus.com
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
Ardelyx, Inc. Sued for Securities Law ViolationsContact the D - GuruFocus.com
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop - MSN
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Ardelyx Executives to Present at Piper Sandler Healthcare Conference | ARDX Stock News - StockTitan
Jefferies optimistic on Ardelyx stock as management navigates reimbursement changes - Investing.com
High Growth Tech Stocks To Explore In November 2024 - Yahoo Finance
Ardelyx appoints new principal accounting officer - Investing.com
US Penny Stocks To Monitor In November 2024 - Simply Wall St
Ardelyx, Inc. (NASDAQ:ARDX) Short Interest Up 5.1% in October - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Gap UpTime to Buy? - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Ardelyx Inc H - GuruFocus.com
Director David Mott Acquires 215,868 Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability (NASDAQ:ARDX) - Seeking Alpha
HC Wainwright Has Bearish Forecast for Ardelyx Q1 Earnings - MarketBeat
Ardelyx (NASDAQ:ARDX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Ardelyx shares downgraded amid sales concerns for XPHOZAH By Investing.com - Investing.com Australia
Ardelyx (NASDAQ:ARDX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Ardelyx shares downgraded amid sales concerns for XPHOZAH - Investing.com India
Ardelyx (NASDAQ:ARDX) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 - Investing.com India
David P. Rosenbaum Sells 27,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 By Investing.com - Investing.com Australia
Ardelyx Beats Q3 Sales Estimates, Shares Climb - MSN
Ardelyx Loses Bid to Block HHS Classification of Kidney Drug - Bloomberg Law
Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update) - MSN
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):